The clinical paradigm shift: Precision tools reshaping oncology
13 Oct 2026
By Herdee Gloriane C. Luna,* MD, FPCP, FPSMO, FPSO
(Note: This article, in partnership with the Philippine Society of Medical Oncology, appeared in the MIMS Oncology magazine, October–November 2026 issue.)
While system navigation remains a challenge locally, global oncology has moved decisively beyond one-size-fits-all cytotoxic chemotherapy. Targeted therapy and immunotherapy now anchor treatment planning across breast, lung, and colorectal cancers, guided by the molecular and immune features of each tumor rather than its site of origin alone. Outcomes improve when treatment matches biology, and biology is now testable at the point of diagnosis. Benefit is increasingly measured not only in response rates, but in years of survival gained.
● Breast cancer: In HER2-positivemetastatic disease, dual HER2 blockade with pertuzumab, trastuzumab, and docetaxel extended median overall survival (OS) by nearly 16 months over trastuzumab and docetaxel alone in the CLEOPATRA trial (57.1 vs. 40.8months; HR 0.69; 8-year survival37% vs. 23%)—unprecedented before targeted therapy. In hormone receptor-positive, HER2-negative disease, CDK4/6inhibitors added to endocrine therapy have produced significant overall survival gains: MONALEESA-7 (ribociclib) showed a median OS of 58.7 versus48.0 months (HR 0.76), and MONARCH-2 (abemaciclib) showed a median OS of 46.7 versus 37.3 months(HR 0.757).
● Lung cancer: In EGFR-mutant advanced non-small cell lung cancer (NSCLC), first-line osimertinib plus platinum-pemetrexed achieved a median OS of 47.5 months in FLAURA2, among the longest reported in a global phase III study of this population, while adjuvant osimertinib raised five-year OS to88% in resectable disease in ADAURA. In ALK-positive NSCLC, alectinib outperformed crizotinib, demonstrating a66.4% 5-year survival rate in the ALESIA study of Asian patients. Perioperative checkpoint inhibition has extended benefit to resectable disease: both nivolumab (CheckMate 77T) and pembrolizumab (KEYNOTE-671) improved pathologic complete response and event-free survival over chemotherapy alone. Biomarker-testing for EGFR, ALK, ROS1, and PD-L1 now directs therapy selection across this continuum.
● Colorectal cancer: In RAS wildtype metastatic disease, FOLFIRI plus cetuximab produced higher response rates and extended median OS to 33months in patients with left-sided primary tumors in the FIRE-3 trial. For the smaller subset with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) tumors, firstline immune checkpoint inhibitors more than doubled progression-free survival and produced a 54.8% 5-year OS rate in landmark trials, despite substantial crossover of chemotherapy patients to immune checkpoint inhibition after progression.
Local integration and access implications
This precision-oncology shift carries profound access implications locally. Molecular and immunohistochemical testing infrastructure remains concentrated in major urban centers, and biomarker-driven agents carry costs that strain out-of-pocket-dependent patients even where PhilHealth and manufacturer access programs help narrow the gap. Building local capacity for reliable, timely biomarker testing, and securing sustainable financing pathways for these therapies, is now as essential to Philippine cancer control as expanding the therapies themselves.
*Fellow, Philippine Society of Medical Oncology (PSMO), Philippine Society of Oncologists (PSO), and Philippine College of Physicians (PCP); Consultant, National Kidney and Transplant Institute (NKTI), St. Luke’s Medical Center, Quezon City (SLMC-QC), and Lung Center of the Philippines (LCP); email: herdeeluna@gmail.com
(Note: This article, in partnership with the Philippine Society of Medical Oncology, appeared in the MIMS Oncology magazine, October–November 2026 issue.)
While system navigation remains a challenge locally, global oncology has moved decisively beyond one-size-fits-all cytotoxic chemotherapy. Targeted therapy and immunotherapy now anchor treatment planning across breast, lung, and colorectal cancers, guided by the molecular and immune features of each tumor rather than its site of origin alone. Outcomes improve when treatment matches biology, and biology is now testable at the point of diagnosis. Benefit is increasingly measured not only in response rates, but in years of survival gained.
● Breast cancer: In HER2-positivemetastatic disease, dual HER2 blockade with pertuzumab, trastuzumab, and docetaxel extended median overall survival (OS) by nearly 16 months over trastuzumab and docetaxel alone in the CLEOPATRA trial (57.1 vs. 40.8months; HR 0.69; 8-year survival37% vs. 23%)—unprecedented before targeted therapy. In hormone receptor-positive, HER2-negative disease, CDK4/6inhibitors added to endocrine therapy have produced significant overall survival gains: MONALEESA-7 (ribociclib) showed a median OS of 58.7 versus48.0 months (HR 0.76), and MONARCH-2 (abemaciclib) showed a median OS of 46.7 versus 37.3 months(HR 0.757).
● Lung cancer: In EGFR-mutant advanced non-small cell lung cancer (NSCLC), first-line osimertinib plus platinum-pemetrexed achieved a median OS of 47.5 months in FLAURA2, among the longest reported in a global phase III study of this population, while adjuvant osimertinib raised five-year OS to88% in resectable disease in ADAURA. In ALK-positive NSCLC, alectinib outperformed crizotinib, demonstrating a66.4% 5-year survival rate in the ALESIA study of Asian patients. Perioperative checkpoint inhibition has extended benefit to resectable disease: both nivolumab (CheckMate 77T) and pembrolizumab (KEYNOTE-671) improved pathologic complete response and event-free survival over chemotherapy alone. Biomarker-testing for EGFR, ALK, ROS1, and PD-L1 now directs therapy selection across this continuum.
● Colorectal cancer: In RAS wildtype metastatic disease, FOLFIRI plus cetuximab produced higher response rates and extended median OS to 33months in patients with left-sided primary tumors in the FIRE-3 trial. For the smaller subset with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) tumors, firstline immune checkpoint inhibitors more than doubled progression-free survival and produced a 54.8% 5-year OS rate in landmark trials, despite substantial crossover of chemotherapy patients to immune checkpoint inhibition after progression.
Local integration and access implications
This precision-oncology shift carries profound access implications locally. Molecular and immunohistochemical testing infrastructure remains concentrated in major urban centers, and biomarker-driven agents carry costs that strain out-of-pocket-dependent patients even where PhilHealth and manufacturer access programs help narrow the gap. Building local capacity for reliable, timely biomarker testing, and securing sustainable financing pathways for these therapies, is now as essential to Philippine cancer control as expanding the therapies themselves.
*Fellow, Philippine Society of Medical Oncology (PSMO), Philippine Society of Oncologists (PSO), and Philippine College of Physicians (PCP); Consultant, National Kidney and Transplant Institute (NKTI), St. Luke’s Medical Center, Quezon City (SLMC-QC), and Lung Center of the Philippines (LCP); email: herdeeluna@gmail.com